Evidence map›Paper›PMID 36418100›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Tocilizumab Attenuates Anti-neutrophil Cytoplasmic Antibody-associated Nephritis Occurring during Abatacept and Adalimumab Therapy for Rheumatoid Arthritis.

Yusuke Yoshimura, Shun Watanabe, Masayuki Yamanouchi, Daisuke Ikuma, Hiroki Mizuno, Akinari Sekine, Eiko Hasegawa, Tatsuya Suwabe, Kei Kono, Keiichi Kinowaki and 3 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Targeting inerleukin-6 for renoprotection.Frontiers in immunology · 2024
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Yusuke YoshimuraNephrology Center, Toranomon Hospital Kajigaya, Japan.
Shun WatanabeNephrology Center, Toranomon Hospital Kajigaya, Japan.
Masayuki YamanouchiNephrology Center, Toranomon Hospital Kajigaya, Japan.
Daisuke IkumaNephrology Center, Toranomon Hospital Kajigaya, Japan.
Hiroki MizunoNephrology Center, Toranomon Hospital Kajigaya, Japan.
Akinari SekineNephrology Center, Toranomon Hospital Kajigaya, Japan.
Eiko HasegawaNephrology Center, Toranomon Hospital Kajigaya, Japan.
Tatsuya SuwabeNephrology Center, Toranomon Hospital Kajigaya, Japan.
Kei KonoDepartment of Pathology, Toranomon Hospital, Japan.
Keiichi KinowakiDepartment of Pathology, Toranomon Hospital, Japan.
Kenichi OhashiDepartment of Pathology, Toranomon Hospital, Japan.
Yoshifumi UbaraNephrology Center, Toranomon Hospital Kajigaya, Japan.
Naoki SawaNephrology Center, Toranomon Hospital Kajigaya, Japan.
Toranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We encountered an 86-year-old Japanese woman who presented with proteinuria (0.4 g/day) and hematuria (red blood cell sediment >100/high-power field), a decreased renal function (serum creatinine, 1.51 mg/dL), and elevated myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) levels (231 IU/mL) during treatment of rheumatoid arthritis with abatacept (a cytotoxic T-lymphocyte-associated antigen 4 agent) and adalimumab (a tumor necrosis factor-α agent). A kidney biopsy showed pauci-immune necrotizing glomerulonephritis, and ANCA-associated vasculitis was diagnosed. Treatment with tocilizumab (an interleukin 6 receptor antibody) monotherapy resulted in the improvement of renal findings and normalization of rheumatoid arthritis disease activity and serum ANCA levels. Tocilizumab can also suppress ANCA-associated vasculitis.

Indexed as

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisArthritis, RheumatoidGlomerulonephritisNephritisAbataceptAdalimumabAged, 80 and overAntibodies, Antineutrophil CytoplasmicAntibodies, Monoclonal, HumanizedFemaleHumansPeroxidaseAbataceptAdalimumabAntibodies, Antineutrophil CytoplasmicAntibodies, Monoclonal, HumanizedPeroxidasetocilizumabANCA-associated glomerulonephritisrheumatoid arthritisTNF-α inhibitortocilizumab

Identifiers

PMID36418100
PMCPMC10400383
OpenAlexW4309644175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.